Myriad Genetics (MYGN) reported $195.9 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.1%. EPS of -$0.03 for the same period compares to -$0.01 a year ago.
The reported revenue represents a surprise of -2.03% over the Zacks Consensus Estimate of $199.96 million. With the consensus EPS estimate being -$0.05, the EPS surprise was +40.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by Product- Prenatal: $49.30 million versus $44.69 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +59.6% change.
- Revenue by Product- Hereditary Cancer: $86.30 million compared to the $92.46 million average estimate based on three analysts. The reported number represents a change of -2% year over year.
- Revenue by Product- Pharmacogenomics: $31 million versus the three-analyst average estimate of $32.46 million. The reported number represents a year-over-year change of -20.3%.
- Revenue by Product- Tumor Profiling: $29.30 million versus the three-analyst average estimate of $30.66 million. The reported number represents a year-over-year change of -5.2%.
View all Key Company Metrics for Myriad here>>>
Shares of Myriad have returned -4.6% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
